308 related articles for article (PubMed ID: 15827572)
1. Effect of increased serotonin levels on [18F]MPPF binding in rat brain: fenfluramine vs the combination of citalopram and ketanserin.
Udo de Haes JI; Cremers TI; Bosker FJ; Postema F; Tiemersma-Wegman TD; den Boer JA
Neuropsychopharmacology; 2005 Sep; 30(9):1624-31. PubMed ID: 15827572
[TBL] [Abstract][Full Text] [Related]
2. Effect of fenfluramine-induced increases in serotonin release on [18F]MPPF binding: a continuous infusion PET study in conscious monkeys.
Udo de Haes JI; Harada N; Elsinga PH; Maguire RP; Tsukada H
Synapse; 2006 Jan; 59(1):18-26. PubMed ID: 16237679
[TBL] [Abstract][Full Text] [Related]
3. Acute and chronic effects of citalopram on 5-HT1A receptor-labeling by [18F]MPPF and -coupling to receptors-G proteins.
Moulin-Sallanon M; Charnay Y; Ginovart N; Perret P; Lanfumey L; Hamon M; Hen R; Fagret D; Ibáñez V; Millet P
Synapse; 2009 Feb; 63(2):106-16. PubMed ID: 19016488
[TBL] [Abstract][Full Text] [Related]
4. Effect of endogenous serotonin on the binding of the 5-hT1A PET ligand 18F-MPPF in the rat hippocampus: kinetic beta measurements combined with microdialysis.
Zimmer L; Mauger G; Le Bars D; Bonmarchand G; Luxen A; Pujol JF
J Neurochem; 2002 Jan; 80(2):278-86. PubMed ID: 11902118
[TBL] [Abstract][Full Text] [Related]
5. Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(IA) receptors in rat brain, assessed using in vivo microdialysis nd PET after fenfluramine.
Hume S; Hirani E; Opacka-Juffry J; Myers R; Townsend C; Pike V; Grasby P
Synapse; 2001 Aug; 41(2):150-9. PubMed ID: 11400181
[TBL] [Abstract][Full Text] [Related]
6. Development of 5-HT1A receptor radioligands to determine receptor density and changes in endogenous 5-HT.
Jagoda EM; Lang L; Tokugawa J; Simmons A; Ma Y; Contoreggi C; Kiesewetter D; Eckelman WC
Synapse; 2006 May; 59(6):330-41. PubMed ID: 16440292
[TBL] [Abstract][Full Text] [Related]
7. The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram.
Arborelius L; Nomikos GG; Hertel P; Salmi P; Grillner P; Höök BB; Hacksell U; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 1996 May; 353(6):630-40. PubMed ID: 8738296
[TBL] [Abstract][Full Text] [Related]
8. Effect of 5-HT1A receptor antagonists on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus.
Invernizzi R; Velasco C; Bramante M; Longo A; Samanin R
Neuropharmacology; 1997; 36(4-5):467-73. PubMed ID: 9225271
[TBL] [Abstract][Full Text] [Related]
9. Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on extracellular 5-HT: this effect persists after repeated citalopram treatment.
Gundlah C; Hjorth S; Auerbach SB
Neuropharmacology; 1997; 36(4-5):475-82. PubMed ID: 9225272
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies.
Cremers TI; Rea K; Bosker FJ; Wikström HV; Hogg S; Mørk A; Westerink BH
Neuropsychopharmacology; 2007 Jul; 32(7):1550-7. PubMed ID: 17203017
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
van Amsterdam C; Seyfried CA
Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
[TBL] [Abstract][Full Text] [Related]
12. In vivo control of 5-hydroxytryptamine release by terminal autoreceptors in rat brain areas differentially innervated by the dorsal and median raphe nuclei.
Hervás I; Bel N; Fernández AG; Palacios JM; Artigas F
Naunyn Schmiedebergs Arch Pharmacol; 1998 Sep; 358(3):315-22. PubMed ID: 9774218
[TBL] [Abstract][Full Text] [Related]
13. Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors.
Romero L; Artigas F
J Neurochem; 1997 Jun; 68(6):2593-603. PubMed ID: 9166757
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterisation of the decrease in 5-HT synthesis in the mouse brain evoked by the selective serotonin re-uptake inhibitor citalopram.
Stenfors C; Yu H; Ross SB
Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):222-32. PubMed ID: 11218075
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade.
Cremers TI; Giorgetti M; Bosker FJ; Hogg S; Arnt J; Mørk A; Honig G; Bøgesø KP; Westerink BH; den Boer H; Wikstrom HV; Tecott LH
Neuropsychopharmacology; 2004 Oct; 29(10):1782-9. PubMed ID: 15138437
[TBL] [Abstract][Full Text] [Related]
16. Acute and chronic effects of citalopram on postsynaptic 5-hydroxytryptamine(1A) receptor-mediated feedback: a microdialysis study in the amygdala.
Bosker FJ; Cremers TI; Jongsma ME; Westerink BH; Wikström HV; den Boer JA
J Neurochem; 2001 Mar; 76(6):1645-53. PubMed ID: 11259482
[TBL] [Abstract][Full Text] [Related]
17. WAY100635-induced augmentation of the 5-HT-elevating action of citalopram: relative importance of the dose of the 5-HT1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor.
Hjorth S; Westlin D; Bengtsson HJ
Neuropharmacology; 1997; 36(4-5):461-5. PubMed ID: 9225270
[TBL] [Abstract][Full Text] [Related]
18. Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo.
Sharp T; Umbers V; Gartside SE
Br J Pharmacol; 1997 Jul; 121(5):941-6. PubMed ID: 9222551
[TBL] [Abstract][Full Text] [Related]
19. LY393558, a 5-hydroxytryptamine reuptake inhibitor and 5-HT(1B/1D) receptor antagonist: effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat.
Mitchell SN; Greenslade RG; Cooper J
Eur J Pharmacol; 2001 Nov; 432(1):19-27. PubMed ID: 11734183
[TBL] [Abstract][Full Text] [Related]
20. A reduced extracellular serotonin level increases the 5-HT1A PET ligand 18F-MPPF binding in the rat hippocampus.
Zimmer L; Rbah L; Giacomelli F; Le Bars D; Renaud B
J Nucl Med; 2003 Sep; 44(9):1495-501. PubMed ID: 12960198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
